CTLA4 and melanoma: For example, in patients with NSCLC treated with anti-programmed cell death (ligand) 1 [PD-(L)1] therapy, SCNAs are lower in patients with durable clinical benefit than in those with nondurable benefit; among patients with melanoma treated with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), those with low SCNA experience longer survival than those with high SCNA12.